share_log

Intuitive Surgical | 10-Q: Q2 2024 Earnings Report

Intuitive Surgical | 10-Q: Q2 2024 Earnings Report

直覺外科公司 | 10-Q：2024財年二季報
美股SEC公告 ·  2024/07/20 05:06

Moomoo AI 已提取核心訊息

Intuitive Surgical reported strong Q2 2024 results with total revenue up 14% to $2.01 billion. Da Vinci procedures grew 17% to approximately 661,000, while Ion procedures surged 82% to 23,200. Instruments and accessories revenue increased 16% to $1.24 billion, and systems revenue rose 14% to $448 million.The company placed 341 da Vinci systems in Q2, including 70 next-generation da Vinci 5 systems, bringing the installed base to 9,203 systems globally. Gross profit margin improved to 68.3% from 66.7% last year. Operating income increased 22% to $567 million, with net income rising to $531.5 million.Looking ahead, Intuitive faces some headwinds including hospital financial pressures, staffing shortages, and increasing competition in markets like China. However, the company remains well-positioned with a strong balance sheet of $7.68 billion in cash and investments. Intuitive continues to invest heavily in R&D and manufacturing capabilities to drive long-term growth in robotic-assisted surgery and minimally invasive care.
Intuitive Surgical reported strong Q2 2024 results with total revenue up 14% to $2.01 billion. Da Vinci procedures grew 17% to approximately 661,000, while Ion procedures surged 82% to 23,200. Instruments and accessories revenue increased 16% to $1.24 billion, and systems revenue rose 14% to $448 million.The company placed 341 da Vinci systems in Q2, including 70 next-generation da Vinci 5 systems, bringing the installed base to 9,203 systems globally. Gross profit margin improved to 68.3% from 66.7% last year. Operating income increased 22% to $567 million, with net income rising to $531.5 million.Looking ahead, Intuitive faces some headwinds including hospital financial pressures, staffing shortages, and increasing competition in markets like China. However, the company remains well-positioned with a strong balance sheet of $7.68 billion in cash and investments. Intuitive continues to invest heavily in R&D and manufacturing capabilities to drive long-term growth in robotic-assisted surgery and minimally invasive care.
直覺外科公司發佈了2024年第二季度強勁的業績，總營業收入同比增長14%，達20.1億美金。達芬奇手術增長了17%，約爲661,000例，而Ion手術激增82%，達23,200例。儀器和配件的營業收入增長16%，達12.4億美金，系統營業收入增長14%，達44800萬美金。該公司在第二季度安裝了341臺達芬奇系統，其中包括70臺下一代達芬奇5系統，使全球已安裝的系統總數達到9,203台。毛利潤率從去年的66.7%提升至68.3%。營業收入增長22%，達56700萬美金，凈利潤上升至53150萬美金。展望未來，直覺公司面臨一些阻力，包括醫院的財務壓力、人員短缺以及在中國等市場競爭的加劇。然而，公司的財務狀況依然良好，擁有76.8億美金的現金和投資。直覺公司繼續在研發和製造能力上進行重磅投資，以推動機器人輔助手術和微創護理的長期增長。
直覺外科公司發佈了2024年第二季度強勁的業績，總營業收入同比增長14%，達20.1億美金。達芬奇手術增長了17%，約爲661,000例，而Ion手術激增82%，達23,200例。儀器和配件的營業收入增長16%，達12.4億美金，系統營業收入增長14%，達44800萬美金。該公司在第二季度安裝了341臺達芬奇系統，其中包括70臺下一代達芬奇5系統，使全球已安裝的系統總數達到9,203台。毛利潤率從去年的66.7%提升至68.3%。營業收入增長22%，達56700萬美金，凈利潤上升至53150萬美金。展望未來，直覺公司面臨一些阻力，包括醫院的財務壓力、人員短缺以及在中國等市場競爭的加劇。然而，公司的財務狀況依然良好，擁有76.8億美金的現金和投資。直覺公司繼續在研發和製造能力上進行重磅投資，以推動機器人輔助手術和微創護理的長期增長。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Pulse Biosciences
    PLSE
    -- 16.600
    Anbio Biotechnology
    NNNN
    -- 7.550
    哈佛生物科學
    HBIO
    -- 0.610
    STAAR Surgical
    STAA
    -- 17.790
    Merit Medical Systems
    MMSI
    -- 103.940
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日